Literature DB >> 11884370

Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor.

B Darblade1, C Pendaries, A Krust, S Dupont, M-J Fouque, J Rami, P Chambon, F Bayard, J-F Arnal.   

Abstract

Although estradiol (E(2)) has been recognized to exert several vasculoprotective effects in several species, its effects in mouse vasomotion are unknown, and consequently, so is the estrogen receptor subtype mediating these effects. We investigated the effect of E(2) (80 microg/kg/day for 15 days) on NO production in the thoracic aorta of ovariectomized C57Bl/6 mice compared with those given placebo. E(2) increased basal NO production. In contrast, the relaxation in response to ATP, to the calcium ionophore A23187, and to sodium nitroprusside was unaltered by E(2), whereas acetylcholine-elicited relaxation was decreased. The abundance of NO synthase I, II, and III immunoreactive proteins (using Western blot) in thoracic aorta homogenates was unchanged by E(2). To determine the estrogen receptor (ER) subtype involved in these effects, transgenic mice in which either the ERalpha or ERbeta has been disrupted were ovariectomized and treated, or not, with E(2). Basal NO production was increased and the sensitivity to acetylcholine decreased in ERbeta knockout mice in response to E(2), whereas this effect was abolished in ERalpha knockout mice. Finally, these effects of E(2) on vasomotion required long-term and/or in vivo exposure, as short-term incubation of aortic rings with 10 nmol/L E(2) in the isolated organ chamber did not elicit any vasoactive effects. In conclusion, this study demonstrates that ERalpha, but not ERbeta, mediates the beneficial effect of E(2) on basal NO production.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884370     DOI: 10.1161/hh0402.105096

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  53 in total

Review 1.  Which gender is better positioned in the process of liver surgery? Male or female?

Authors:  Yukihiro Yokoyama; Masato Nagino; Yuji Nimura
Journal:  Surg Today       Date:  2007-09-26       Impact factor: 2.549

Review 2.  From in vivo gene targeting of oestrogen receptors to optimization of their modulation in menopause.

Authors:  Jean-François Arnal; Françoise Lenfant; Gilles Flouriot; Florence Tremollières; Henrik Laurell; Coralie Fontaine; Andrée Krust; Pierre Chambon; Pierre Gourdy
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

3.  17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.

Authors:  Tim Lahm; Marjorie Albrecht; Amanda J Fisher; Mona Selej; Neel G Patel; Jordan A Brown; Matthew J Justice; M Beth Brown; Mary Van Demark; Kevin M Trulock; Dino Dieudonne; Jagadeshwar G Reddy; Robert G Presson; Irina Petrache
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

4.  Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.

Authors:  Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

5.  Sympathetic restraint of muscle blood flow during hypoxic exercise.

Authors:  Michael K Stickland; Curtis A Smith; Benjamin J Soriano; Jerome A Dempsey
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-03-18       Impact factor: 3.619

6.  Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats.

Authors:  Hongwei Si; Dongmin Liu
Journal:  J Nutr       Date:  2008-02       Impact factor: 4.798

Review 7.  Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels.

Authors:  Dia A Smiley; Raouf A Khalil
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 8.  From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis.

Authors:  Stavros C Manolagas
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

9.  The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol.

Authors:  Audrey Billon-Galés; Coralie Fontaine; Cédric Filipe; Victorine Douin-Echinard; Marie-José Fouque; Gilles Flouriot; Pierre Gourdy; Françoise Lenfant; Henrik Laurell; Andrée Krust; Pierre Chambon; Jean-François Arnal
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

10.  Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease.

Authors:  Reagan L Ross; Michelle R Serock; Raouf A Khalil
Journal:  Curr Cardiol Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.